{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"SMAD4 encodes a tumor suppressor and transcription factor that is a downstream effector in the TGF-\u00df signal transduction pathway. SMAD4 is frequently mutated in pancreatic and colorectal cancer and infrequently mutated in various other cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"04/07/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "25275298"
      ]
    },
    "description":"The SMAD4 H132Y mutation is located in the MH1 domain, which is important for DNA binding. Cell lines expressing this mutation did not respond to TGF-beta stimulation, suggesting that this mutation is loss-of-function (PMID: 25275298).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"H132Q",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":4089,
    "hgvs":null,
    "hugoSymbol":"SMAD4",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The SMAD4 H132Q mutation has not been functionally or clinically validated. However, SMAD4 H132Y is likely oncogenic, and therefore SMAD4 H132Q is considered likely oncogenic.",
  "vus":false
}